Bristol-Myers Squibb Company and Pfizer have announced that the FDA has accepted for review a Supplemental New Drug Application (sNDA) for ELIQUIS ® (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE.
Thee Generic Pharmaceutical Association (GPhA) has released the fifth annual report, Generic...
State health researchers have discovered the first new strain of botulism in four decades, but...
The detached dad, turning up his nose at diapering and too busy to bathe, dress and play with his kids, is mostly a myth, a big government survey suggests. Most American fathers say they are heavily involved in hands-on parenting, the researchers found.
Federal regulators appear to be considering a proposal by Amarin in regard to the structure of a drug study that could lead to wider uses for its fish-oil pill. The drug Vascepa is a prescription-strength form of an omega-3 fatty acid. It is Amarin's only product and it was approved last year for a relatively narrow use in patients with unusually high triglyceride levels.
Merck Launches New Business Focused on Comprehensive, Evidence-Based Weight Management Interventions in the U.S.December 20, 2013 9:20 am | Comments
Merck has announced the launch of a new business focused on providing comprehensive, evidence-based weight management interventions for employers, hospitals, medical groups, health plans and patients.
Walgreen says its fiscal first quarter earnings soared 68 per cent, helped in part by investments that the nation's largest drugstore chain has made in other companies. Walgreen Co. says its results were helped by its stakes in European health and beauty retailer Alliance Boots and pharmaceutical wholesaler AmerisourceBergen Corp.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization for Sirturo (bedaquiline) for use as part of a combination therapy for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
Jazz Pharmaceuticals PLC plans to buy drug maker Gentium SpA for roughly $1 billion in a cash deal aimed at expanding its rare disease drug portfolio. Shares of Jazz jumped nearly 6 percent to $121.50 in after-hours trading following the announcement.
Problems with the government's main health care overhaul website carry a bigger risk than frequent crashes: Higher prices could follow for many Americans if technical troubles scare off young people.
U.S. health authorities have issued a travel advisory for the French Caribbean dependency of St. Martin because of a mosquito-borne viral disease that is apparently being spread locally at the start of the winter tourist season.
Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion. The two firms said Thursday drug and chemical company Bayer will make a cash offer of 362 kroner ($59.24) per Algeta share.
AstraZeneca PLC will buy out Bristol-Myers Squibb Co.'s stake in their partnership to develop and sell diabetes drugs in a deal worth $4.1 billion — seizing an opportunity to serve the projected explosion of patients suffering from the disease.
Alimera Sciences Inc. and pSivida Corp. shares surged in extended trading Wednesday after the FDA said that the companies don't need to face an advisory committee nor conduct any new clinical trials prior to the agency making a decision about whether to approve their eye disease treatment.
Many older adults with high blood pressure can be treated less aggressively, which could mean taking fewer pills to get it under control, according to new treatment guidelines from an expert panel. But not all experts are on board with the advice.
The Food and Drug Administration has approved a new once-a-day inhaler from GlaxoSmithKline PLC that combines two drugs to treat lung disease.
The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have announced the launch of a joint initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals.
Pfizer has named Albert Bourla as Group President of the Vaccines, Oncology and Consumer Healthcare business effective January 1, 2014. Amy Schulman and Pfizer have agreed to separate.